In June 2021, a class action lawsuit filed against Johnson & Johnson alleged that OGX Biotin + Collagen Shampoo and Conditioners contained DMDM Hydantoin, a formaldehyde-releasing preservative linked to severe hair loss and scalp irritation. The lawsuit, filed by Larissa Whipple in Illinois District Court, raised a critical question: Why did J&J continue using an ingredient they themselves had acknowledged as damaging years earlier?
The core allegation centers on DMDM Hydantoin, a chemical preservative that releases formaldehyde over time. According to the lawsuit and industry reports, J&J committed in 2012 to remove formaldehyde and similar ingredients from their personal care products by 2015, yet OGX products containing DMDM continued to be sold until September 2021—six years after their own deadline. This gap between what J&J knew and what they did became the basis for the class action claim.
Table of Contents
- What Is DMDM Hydantoin and Why Did It Matter in OGX Shampoo?
- The Critical Timeline—When Did Johnson & Johnson Know?
- The Class Action Lawsuit and Its Current Status
- Comparative Cases—What Settlements in Similar Hair Care Litigation Have Looked Like
- Who Was Affected and What Symptoms Were Reported?
- The Broader Context—DMDM Hydantoin Restrictions and Industry Changes
- What This Case Means for Consumers and Future Litigation
- Frequently Asked Questions
What Is DMDM Hydantoin and Why Did It Matter in OGX Shampoo?
DMDM Hydantoin is a preservative used in personal care products to prevent bacterial and fungal growth. The ingredient works by slowly releasing formaldehyde, which acts as an antimicrobial agent. While formaldehyde in trace amounts is considered acceptable in many cosmetic products, consumers and regulators have raised concerns about accumulative exposure, particularly in products used repeatedly on the scalp and hair.
The specific OGX products at issue—the Biotin + Collagen line of shampoos and conditioners—were marketed to consumers as hair-strengthening treatments. However, according to the class action lawsuit, rather than strengthening hair, the products caused the opposite effect for many users. Complaints documented in the lawsuit included significant hair loss, scalp irritation, allergic reactions, and in some cases, permanent hair damage. The allegation was that DMDM Hydantoin was the culprit, either through direct irritation or through the formaldehyde it released during product use and storage.
The Critical Timeline—When Did Johnson & Johnson Know?
The most damaging aspect of this case from J&J’s perspective is the timeline. In 2012, Johnson & Johnson publicly acknowledged the potential damaging effects of DMDM Hydantoin and similar formaldehyde-releasing preservatives. In response, J&J committed to phasing out these ingredients from their personal care product lines by 2015. However, this deadline came and went without OGX products being reformulated.
The lawsuit alleges that despite this internal commitment, OGX Biotin + Collagen products containing DMDM Hydantoin remained on shelves and continued to be sold to consumers throughout 2016, 2017, 2018, 2019, and 2020. This is the critical gap: J&J knew the ingredient was problematic, promised to remove it by 2015, and then continued selling products containing it for another six years. The company did not cease manufacturing OGX products with DMDM Hydantoin until September 2021, just months before the class action was filed in June 2021. It is important to note that this does not mean all OGX products disappeared from store shelves in September 2021—existing inventory likely continued to sell for months afterward. For consumers who purchased these products during the extended timeline, the question became whether J&J should have acted faster and whether they should face liability for the alleged harm caused by hair loss and scalp damage.
The Class Action Lawsuit and Its Current Status
Larissa Whipple’s lawsuit against Johnson & Johnson was filed on June 7, 2021, in the Illinois District Court. The case alleged that OGX Biotin + Collagen Shampoo and Conditioners were defectively designed, improperly labeled, and that consumers were not adequately warned about the risks of hair loss and scalp irritation. The lawsuit sought damages for affected consumers and sought class action certification to represent all individuals who purchased the products during the relevant time period. However, as of March 2026, the litigation remains in an unclear state.
Court filings from March 2022 indicate that DMDM-related lawsuits were dismissed, with reports suggesting a possible secret settlement between the parties. No publicly announced settlement amount or payout structure has been confirmed for the OGX DMDM class action as of now. This is a common occurrence in high-profile consumer litigation—companies and plaintiffs’ attorneys sometimes reach confidential settlements that do not require public disclosure of all terms. Without access to court records or a public settlement notice, consumers affected by these products cannot easily determine whether they are eligible for compensation or how much they might receive.
Comparative Cases—What Settlements in Similar Hair Care Litigation Have Looked Like
Understanding the potential value of an OGX settlement requires looking at comparable cases in the hair care and personal care products industry. One similar case involved TRESemmé hair products containing formaldehyde-releasing preservatives. In that litigation, Unilever settled for $10.2 million to resolve claims that Suave keratin products caused hair damage. The settlement covered medical monitoring and product replacement claims for class members who purchased the affected products.
Another historical reference involves Vogue International, which owned the Organix brand before it was rebranded and eventually sold to Johnson & Johnson (the products were subsequently rebranded as OGX). Vogue International paid a $6.5 million settlement in an unrelated labeling dispute regarding hair care products. While these figures do not directly indicate what an OGX settlement might be, they provide a baseline for understanding the range of settlements in this product category. The tradeoff in settlements like these is that class members rarely receive the full settlement amount—administrative costs, legal fees, and claims processing typically consume 40-60% of the total settlement fund, leaving individual consumers with much smaller payments, often in the range of $10 to $100 per claimant depending on the class size.
Who Was Affected and What Symptoms Were Reported?
According to the lawsuit and consumer reports, individuals who used OGX Biotin + Collagen Shampoo and Conditioners experienced various adverse effects. The most commonly reported symptom was significant hair loss, which many users described as occurring within weeks of using the product. Some consumers reported that their hair became brittle, thin, or stopped growing altogether. Others experienced scalp irritation, redness, burning sensations, and allergic reactions including hives and dermatitis.
One important limitation to understand is that not all hair loss can be attributed to a shampoo product. Hair loss has multiple causes including genetics, hormonal changes, stress, illness, and nutritional deficiencies. This creates a challenge in class action litigation: How do you prove that a specific product caused harm when the alleged harm (hair loss) has multiple potential causes? The class action lawsuit addressed this by focusing on the timing and severity of complaints, the pattern of reports across multiple consumers, and the known properties of DMDM Hydantoin as an irritant. However, this also means that not every person who experienced hair loss while using OGX would necessarily qualify for compensation—the claims process typically requires some documentation or evidence that the product was the likely cause.
The Broader Context—DMDM Hydantoin Restrictions and Industry Changes
DMDM Hydantoin has become increasingly restricted in the personal care industry over the past decade. The European Union has implemented stricter regulations on formaldehyde-releasing preservatives, and many major cosmetic brands have voluntarily phased out DMDM Hydantoin in response to consumer demand and regulatory pressure. The fact that J&J committed to removing the ingredient by 2015 suggests that the company was already aware of industry trends and consumer preferences shifting away from formaldehyde-based preservatives.
By the time the OGX lawsuit was filed in 2021, DMDM Hydantoin was already considered outdated and problematic by many in the industry. Newer preservative systems, including natural alternatives like plant-based preservatives and advanced synthetic preservatives with better safety profiles, had become widely available. This context is important because it strengthens the plaintiffs’ argument that J&J had both the knowledge and the means to reformulate OGX products years earlier but chose not to do so, likely due to cost considerations and the desire to avoid admitting prior wrongdoing.
What This Case Means for Consumers and Future Litigation
The OGX DMDM Hydantoin case represents an important moment in consumer product liability litigation. It demonstrates that companies can face significant legal consequences when they make public commitments to remove problematic ingredients but then fail to follow through in a timely manner. The case also highlights the challenge consumers face in protecting themselves from harmful products—many people had no way of knowing that OGX continued to use DMDM Hydantoin despite J&J’s earlier acknowledgment of its dangers.
Looking forward, this litigation may influence how other companies manage the removal of problematic ingredients from their product lines. The gap between J&J’s 2012 commitment and the 2021 cessation of OGX product manufacturing with DMDM Hydantoin serves as a cautionary tale about the importance of transparency and timely follow-through on safety promises. For consumers who used these products and experienced hair loss or scalp damage, the case underscores the value of documenting health issues and preserving product packaging and receipts, as these become critical evidence in class action settlements.
Frequently Asked Questions
What exactly is DMDM Hydantoin?
DMDM Hydantoin is a synthetic preservative that releases formaldehyde over time to prevent bacterial and fungal contamination in personal care products. While small amounts of formaldehyde are considered acceptable in cosmetics by regulatory agencies, concerns about accumulative exposure and scalp irritation led many companies, including Johnson & Johnson, to commit to phasing it out.
How do I know if my OGX products contained DMDM Hydantoin?
Check the ingredient list on the back of the product bottle or packaging. DMDM Hydantoin will be listed among the ingredients. Products from the OGX Biotin + Collagen line manufactured before September 2021 are the primary focus of the lawsuit, though other OGX products may have also contained the ingredient.
Is there an active settlement for the OGX lawsuit?
As of March 2026, no publicly confirmed settlement has been announced for the DMDM Hydantoin OGX class action. Court filings from 2022 suggest the case may have been settled confidentially, but details remain unclear. Checking official court websites or settlement notice websites periodically is recommended.
What evidence do I need to file a claim?
Typical class action settlements require proof of purchase (receipt or credit card statement showing you bought the product during the relevant period) and documentation of harm (medical records from a dermatologist, photographs of scalp damage, or written records of significant hair loss that coincided with use of the product).
How much compensation might affected consumers receive?
Based on similar settlements in the hair care industry, payouts to individual class members typically range from $10 to $100 per claim, though this depends on the total settlement amount, the size of the class, and the claims approval rate. Administrative costs and legal fees typically consume 40-60% of the total settlement fund.
What should I do if I have a claim?
First, monitor official settlement notice websites and the Illinois District Court docket for any public settlement announcement related to the OGX DMDM Hydantoin litigation. Once a settlement is confirmed and a claim window opens, submit your claim with documentation of purchase and any medical evidence of harm. If no public settlement emerges, consult with a consumer protection attorney about your options.